Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/antengene-announces-one-oral-and-three-poster-presentations-at-asco-2024-302127183.html
https://www.prnewswire.com/news-releases/antengene-presents-four-preclinical-posters-at-aacr-2024-302107397.html
https://www.prnewswire.com/news-releases/antengene-announces-full-year-2023-financial-results-highlights-clinical-progress-across-first-in-class-best-in-class-pipeline-302096838.html
https://www.prnewswire.com/news-releases/antengene-initiates-phase-ii-dose-expansion-study-of-claudin-18-2-adc-atg-022-in-china-and-australia-302094388.html
https://www.prnewswire.com/news-releases/antengene-publishes-preclinical-paper-on-pd-l14-1bb-bispecific-antibody-atg-101-in-renowned-oncology-journal-cancer-research-302093174.html
https://www.prnewswire.com/news-releases/antengene-to-present-four-preclinical-abstracts-at-aacr-2024-highlighting-focus-on-cancer-immunology-targeted-agents-and-novel-technology-platforms-302080156.html
https://www.prnewswire.com/news-releases/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list-302014837.html
https://www.prnewswire.com/news-releases/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list-302014837.html
https://www.prnewswire.com/news-releases/antengene-announces-the-study-of-anti-cd24-monoclonal-antibody-atg-031-dosed-its-first-patient-in-the-united-states-302010758.html
https://www.prnewswire.com/news-releases/antengene-presents-encouraging-clinical-data-from-four-pipeline-programs-at-the-2023-rd-day-301990840.html